- Home
- MVO vs OTLK Comparison
MVO vs OTLK Comparison
Compare MVO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVO
- OTLK
- Stock Information
- Founded
- MVO 2006
- OTLK 2010
- Country
- MVO United States
- OTLK United States
- Employees
- MVO N/A
- OTLK N/A
- Industry
- MVO Oil & Gas Production
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MVO Energy
- OTLK Health Care
- Exchange
- MVO Nasdaq
- OTLK Nasdaq
- Market Cap
- MVO 49.9M
- OTLK 42.8M
- IPO Year
- MVO N/A
- OTLK 2016
- Fundamental
- Price
- MVO $4.03
- OTLK $1.55
- Analyst Decision
- MVO
- OTLK Buy
- Analyst Count
- MVO 0
- OTLK 5
- Target Price
- MVO N/A
- OTLK $5.25
- AVG Volume (30 Days)
- MVO 55.1K
- OTLK 3.5M
- Earning Date
- MVO 01-01-0001
- OTLK 12-26-2025
- Dividend Yield
- MVO 17.46%
- OTLK N/A
- EPS Growth
- MVO N/A
- OTLK N/A
- EPS
- MVO 1.46
- OTLK N/A
- Revenue
- MVO N/A
- OTLK $1,505,322.00
- Revenue This Year
- MVO N/A
- OTLK N/A
- Revenue Next Year
- MVO N/A
- OTLK $342.80
- P/E Ratio
- MVO $7.29
- OTLK N/A
- Revenue Growth
- MVO N/A
- OTLK N/A
- 52 Week Low
- MVO $8.85
- OTLK $0.79
- 52 Week High
- MVO $13.95
- OTLK $6.06
- Technical
- Relative Strength Index (RSI)
- MVO 17.95
- OTLK 64.92
- Support Level
- MVO $4.21
- OTLK $1.21
- Resistance Level
- MVO $4.50
- OTLK $1.83
- Average True Range (ATR)
- MVO 0.19
- OTLK 0.11
- MACD
- MVO -0.04
- OTLK 0.02
- Stochastic Oscillator
- MVO 0.00
- OTLK 59.29
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.